Vaccibody Becomes Nykode Therapeutics - a New Name and Identity to Signify a New Phase of Growth and Development
Nykode Therapeutics (formerly Vaccibody*)) (Euronext Growth (Oslo): VACC (ticker will soon be changed)), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that the Company is changing its name to reflect its exciting development and mark a milestone in our journey of growth and transformation. It acts as a visible symbol of a new phase of opportunity based on collaborations, internationalization, and future ambitions. And it conveys how we are truly starting to realize our vision of being a leading immunotherapy platform company, breaking down the boundaries of conventional drug design to unlock the future of medicine.
The Company’s new name is inspired by its Norwegian roots and links to our platform’s modularity. Nykode translates as ‘new code’, playing on the potential of our technology to generate novel codes and create innovative patient therapies.
Michael Engsig, CEO of Nykode Therapeutics: “Over the last few years, the Company has made significant steps forward. We have reported promising clinical data, continued to grow our pipeline and forged significant partnerships.” Michael Engsig added, “We continue our exciting transformation from a two-asset focused company to a fully-fledged platform biotech company. During the past year, we have increased the number of talented colleagues, made important additions to our senior management team, invested strategically, and expanded internationally. This positive evolution, combined with our future ambitions, inspired the need to revisit our brand.”
Agnete B. Fredriksen, Chief Innovation & Strategy Officer of Nykode Therapeutics, continued, “The challenge of changing our name was to consolidate everything we have achieved to date with our future plans to expand, and combine this into a powerful new brand.” Agnete B. Fredriksen added, “We have shown that we can generate novel molecules by combining multiple different genes or codes to generate new medicines with unique properties. We will build further on this know-how, driven by our guiding purpose to push the boundaries of human advancement by rethinking conventional drug design. We want to express how our platform’s intelligent modular design and tailored hyper targeting may deliver game-changing medicines for patients. This vision aims to create innovative therapies and continues to broaden our reach into multiple therapeutic areas, both with and without our partners. In essence, we believe that our new name, Nykode, uniquely captures our progress and possibilities.”
Read more about the journey and inspiration regarding our new name, logo, and visual identity on our new website, nykode.com.
*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.
About Nykode Therapeutics
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Nykode Therapeutics’ modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumours and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.
The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and collaborate with Adaptive Biotechnologies for COVID-19 T cell vaccine development.
Nykode Therapeutics’ shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC (ticker will soon be changed). Further information about Nykode Therapeutics may be found at http://www.nykode.com
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006744/en/
Contact information
Contact for Nykode Therapeutics AS:
CEO Michael Engsig
Nykode Therapeutics AS
ir@nykode.com
Nykode Therapeutics AS
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ-GfK Wins Radio and TV Measurement Contracts in South Africa15.10.2025 12:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, is proud to announce that the Broadcast Research Council of South Africa (BRC) has appointed GfK, an NIQ company, to provide comprehensive measurement of radio and television audiences nationwide. This milestone marks a new era for South African media, marketing, and advertising, empowering the industry with robust, innovative, and actionable audience data. Following a rigorous and competitive selection process, the BRC first awarded the Radio Audience Measurement System (RAMS) contract to GfK in June 2025. The first round of radio data collection is already underway and initial insights will be released in Q1 2026. In addition, GfK will also design and deploy South Africa’s new Total Video Measurement service, aligning the country’s TV currency with the way audiences consume content today. Gary Whitaker, CEO of the BRC, commented, “We are pleased to partner with GfK and NIQ for the next chapter of audience measurement in South
Bentley Systems Advances Infrastructure AI with New Applications and Industry Collaboration15.10.2025 10:53:00 EEST | Press release
Bentley Systems’ Year in Infrastructure 2025 – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today unveiled new infrastructure AI capabilities at its Year in Infrastructure conference. Bentley also announced an Infrastructure AI co-innovation initiative, inviting engineering firms and asset owners to collaborate on the next generation of AI workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015714746/en/ Bentley's OpenSite+, the first engineering application leveraging generative AI for civil site design, is now in limited availability. It delivers projects up to 10 times faster without sacrificing accuracy. (Image courtesy of Bentley Systems) “AI is poised to transform infrastructure,” said Bentley CEO Nicholas Cumins. “At Bentley, our vision is for AI to empower infrastructure engineers—not replace them. Trustworthy AI, built on infrastructure context, can improve e
Bentley Systems Announces Bentley Infrastructure Cloud Connect15.10.2025 10:51:00 EEST | Press release
(Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced Bentley Infrastructure Cloud Connect, the new foundational layer of Bentley Infrastructure Cloud. Connect provides a connected data environment and unified experience for infrastructure professionals interacting with project and asset data, improving collaboration across the infrastructure lifecycle and value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015261978/en/ Bentley Systems announced Bentley Infrastructure Cloud Connect, providing a trusted foundation to connect data and people across the infrastructure lifecycle and value chain. (Image courtesy of Bentley Systems) “Infrastructure data lives everywhere—in models, PDFs, inspection forms, photos, IoT sensors, and more—and it’s rarely connected,” said Julien Moutte, chief technology officer, Bentley S
Bentley Systems Bolsters Cesium with Reality Modeling Capabilities, Brings Geospatial Context to Infrastructure Engineering15.10.2025 10:50:00 EEST | Press release
(Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the availability of reality modeling services in Cesium, advancing its open platform for the built and natural environment. It also unveiled geospatial capabilities for project delivery and asset performance and a new immersive engagement application for infrastructure teams and stakeholders, all powered by Cesium. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015286327/en/ Bentley announced the availability of reality modeling services in Cesium, advancing its open platform for the built and natural environment. (Image courtesy of Bentley Systems) Since acquiring Cesium a year ago, Bentley has made significant progress in integrating technologies from both companies, powering its own products and empowering developers to build applications that visualize infrastru
SkySparc Acquires Inovotek Solutions to Strengthen Its Capital Markets Expertise and Expand Delivery Across Murex, Calypso, and FIS Platforms15.10.2025 10:00:00 EEST | Press release
SkySparc, a trusted global provider of digital transformation solutions for treasury and finance institutions, today announced the acquisition of Inovotek Solutions (“Inovotek” or the “Company”), a specialist provider of transformation services to capital markets and financial institutions. Financial terms were not disclosed. The acquisition will bolster SkySparc's position as a premier provider of comprehensive digital transformation services to capital markets clients globally. It will address critical client challenges, including regulatory compliance and complex re-platforming initiatives. Additionally, SkySparc will expand its expertise across leading trading and risk management platforms such as Murex, Calypso, and FIS. By combining Inovotek’s program management expertise with SkySparc’s established managed services and proprietary software – OmniFi and Optimizer – the Company will deliver a robust and complete offering capable of addressing the most complex and demanding client
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom